Alnylam Pharmaceuticals (ALNY) and Ionis Pharmaceuticals (IONS) have both developed effective treatments for a rare nerve disorder known as familial amyloid polyneuropathy (FAP). Which drug is better? Dueling clinical trial presentations made Thursday at a research meeting in Paris gave investors a unique opportunity to compare.
The winner: Alnylam.
About the Author Reprints
